Vertex Pharmaceuticals (VRTX) Q4 and Annual 2025 Earnings
Vertex Pharmaceuticals reported Q4 2025 revenue of $3.2B (+9.5% YoY), beat analyst consensus of $3.2B by $5.8M. Diluted EPS came in at $5.03 (+26.4% YoY), missed the $5.11 consensus by $0.08. Vertex Pharmaceuticals reports across 3 business segments, led by Cystic Fibrosis (CF), Hematology and Pain Management, and Specialty Pipeline Programs.
Financial Snapshot
Trailing eight quarters through Q4 2025
Q4 2025 Earnings FAQ
Common questions about Vertex Pharmaceuticals's Q4 2025 earnings report.
Vertex Pharmaceuticals (VRTX) reported Q4 2025 earnings on February 12, 2026 after market close.
Vertex Pharmaceuticals reported revenue of $3.2B and diluted EPS of $5.03 for Q4 2025.
Revenue beat the consensus estimate of $3.2B by $5.8M. EPS missed the consensus estimate of $5.11 by $0.08.
Compared to the same quarter a year prior, revenue grew 9.5% from $2.9B a year earlier and diluted EPS grew 26.4% from $3.98.
Vertex Pharmaceuticals reports across 3 business segments, led by Cystic Fibrosis (CF), Hematology and Pain Management, and Specialty Pipeline Programs. Segment-level financials are available on the company's metrics pages.
You can read the 8-K earnings release (0000875320-26-000034) and the 10-K periodic report (0000875320-26-000056) directly on SEC EDGAR. The filing index links above go to sec.gov.